Analysis of clinical characteristics of 457 patients with heart failure treated with lyophilized Yiqifumai injection:a multicenter real-world study
10.3969/j.issn.1008-9691.2024.04.009
- VernacularTitle:注射用益气复脉(冻干)治疗457例心力衰竭患者的临床特征分析
- Author:
Xuezheng LIU
1
;
Guohua SHI
;
Lijie WANG
;
Rui WANG
;
Shichao LYU
Author Information
1. 天津中医药大学第一附属医院老年病科,国家中医针灸临床医学研究中心,天津 300381
- Keywords:
Lyophilized Yiqifumai injection;
Heart failure;
Real-world
- From:
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
2024;31(4):433-437
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical characteristics of patients with heart failure(HF)treated with lyophilized Yiqifumai injection based on real-world data,providing evidence for the rational and standardized use of Yiqifumai injection.Methods Hospitalized HF patients from 81 hospitals across China were included in this study between April and November 2023.We collected demographics information[sex,age,New York Heart Association(NYHA)functional classification],length of hospital stay,duration of medication use,and biomarkers such as N-terminal pro-brain natriuretic peptide(NT-proBNP),left ventricular ejection fraction(LVEF),and left ventricular end-diastolic diameter(LVEDD).Clinical features of HF patients treated with Yiqifumai injection were analyzed,and comparisons were made among different HF subtypes.Results A total of 457 HF patients were included:96 with heart failure with reduced ejection fraction(HFrEF),70 with HF with mildly reduced ejection fraction(HFmrEF),and 291 with HF with preserved ejection fraction(HFpEF).The majority of HFpEF type and HFrEF type patients were classified as NYHA class Ⅲ[48.1％(140/291)and 54.2％(52/96),respectively],while most HFmrEF type patients were classified as class Ⅳ[41.4％(29/70)].The longest average hospital stay was recorded in HFmrEF type patients[(9.30±3.02)days],while the shortest was recorded in HFrEF type patients[(8.77±3.11)days].The shortest average medication duration was found in the HFrEF type[(8.54±2.95)days],while the longest was observed in HFpEF type patients[(8.82±2.82)days].Serum NT-proBNP levels were significantly decreased post-treatment in all three types[ng/L:HFrEF was 2 435.00(1 169.25,5 607.75)vs.5 334.00(2 077.33,9 108.88),HFmrEF type was 2 313.25(598.09,6 224.67)vs.4 559.21(1 325.75,8 922.75),HFpEF type was 824.00(169.46,2298.75)vs.1 265.00(215.00,3 458.80),all P<0.05],with the most pronounced decrease observed in the HFrEF type.LVEF was significantly improved in the HFrEF type[0.340(0.290,0.378)vs.0.336(0.280,0.360),P<0.05],while no significant changes were noted in the HFmrEF type and HFpEF type.No significant differences in LVEDD were found before and after treatment in any type(all P>0.05).Conclusion In the real-world setting,the advantages of Yiqifumai injection in treating HFrEF are more pronounced,while further evidence from evidence-based medicine is needed to support its use in other types of heart failure.
